BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
AstraZeneca
Bayer
Merck Sharp & Dohme Corp.
OSI Pharmaceuticals
Yale University
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01248247
First received: November 23, 2010
Last updated: March 14, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)